Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis

详细信息    查看全文

• 作者：Romana Meletta ; Adrienne Müller Herde ; Patrick Dennler ; Eliane Fischer…
• 关键词：Co ; stimulatory molecules ; CD80 ; CD86 ; Belatacept ; Atherosclerosis ; Inflammation ; Imaging
• 刊名：EJNMMI Research
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：6
• 期：1
• 全文大小：3,673 KB
• 参考文献：1.Subramanian M, Tabas I. Dendritic cells in atherosclerosis. Semin Immunopathol. 2014;36(1):93–102. doi:10.​1007/​s00281-013-0400-x .CrossRef PubMed PubMedCentral
  2.Collins M, Ling V, Carreno BM. The B7 family of immune-regulatory ligands. Genome Biol. 2005;6(6):223. doi:10.​1186/​gb-2005-6-6-223 .CrossRef PubMed PubMedCentral
  3.Keir ME, Sharpe AH. The B7/CD28 costimulatory family in autoimmunity. Immunol Rev. 2005;204:128–43. doi:10.​1111/​j.​0105-2896.​2005.​00242.​x .CrossRef PubMed
  4.Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med. 2008;14(12):550–9. doi:10.​1016/​j.​molmed.​2008.​09.​010 .CrossRef PubMed PubMedCentral
  5.Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2004;109(16):2009–15. doi:10.​1161/​01.​CIR.​0000127121.​16815.​F1 .CrossRef PubMed
  6.Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, de Vries MR, et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol. 2013;168(3):1965–74. doi:10.​1016/​j.​ijcard.​2012.​12.​085 .CrossRef PubMed
  7.Müller A, Mu L, Meletta R, Beck K, Rancic Z, Drandarov K, et al. Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules. Int J Cardiol. 2014;174(3):503–15. doi:10.​1016/​j.​ijcard.​2014.​04.​071 .CrossRef PubMed
  8.Erbel C, Sato K, Meyer FB, Kopecky SL, Frye RL, Goronzy JJ, et al. Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol. 2007;102(2):123–32. doi:10.​1007/​s00395-006-0636-x .CrossRef PubMed
  9.Dietel B, Cicha I, Voskens CJ, Verhoeven E, Achenbach S, Garlichs CD. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis. 2013;230(1):92–9. doi:10.​1016/​j.​atherosclerosis.​2013.​06.​014 .CrossRef PubMed
  10.Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res. 1998;37(3):799–810.CrossRef PubMed
  11.Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis. 2004;176(1):101–10. doi:10.​1016/​j.​atherosclerosis.​2004.​04.​027 .CrossRef PubMed
  12.Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3):443–53. doi:10.​1111/​j.​1600-6143.​2005.​00749.​x .CrossRef PubMed
  13.Bernett MJ, Chu SY, Leung I, Moore GL, Lee SH, Pong E, et al. Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn. MAbs. 2013;5(3):384–96. doi:10.​4161/​mabs.​23976 .CrossRef PubMed PubMedCentral
  14.Cooper MS, Sabbah E, Mather SJ. Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes. Nat Protoc. 2006;1(1):314–7. doi:10.​1038/​nprot.​2006.​49 .CrossRef PubMed
  15.Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ, et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation. 2006;113(23):2744–53. doi:10.​1161/​CIRCULATIONAHA.​105.​590018 .CrossRef PubMed
  16.Kuhlmann MT, Cuhlmann S, Hoppe I, Krams R, Evans PC, Strijkers GJ et al. Implantation of a carotid cuff for triggering shear-stress induced atherosclerosis in mice. J Vis Exp. 2012(59). doi:10.3791/3308
  17.Olsson C, Michaelsson E, Parra E, Pettersson U, Lando PA, Dohlsten M. Biased dependency of CD80 versus CD86 in the induction of transcription factors regulating the human IL-2 promoter. Int Immunol. 1998;10(4):499–506.CrossRef PubMed
  18.Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood. 2003;101(1):202–9. doi:10.​1182/​blood-2002-06-1668 .CrossRef PubMed
  19.Knogler K, Grunberg J, Novak-Hofer I, Zimmermann K, Schubiger PA. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Nucl Med Biol. 2006;33(7):883–9. doi:10.​1016/​j.​nucmedbio.​2006.​08.​001 .CrossRef PubMed
  20.Linehan SA. The mannose receptor is expressed by subsets of APC in non-lymphoid organs. BMC Immunol. 2005;6:4. doi:10.​1186/​1471-2172-6-4 .CrossRef PubMed PubMedCentral
  21.Le A, Saverin M, Hand AR. Distribution of dendritic cells in normal human salivary glands. Acta Histochem Cytochem. 2011;44(4):165–73. doi:10.​1267/​ahc.​11010 .CrossRef PubMed PubMedCentral
  22.Vasquez KO, Casavant C, Peterson JD. Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging. PLoS One. 2011;6(6), e20594. doi:10.​1371/​journal.​pone.​0020594 .CrossRef PubMed PubMedCentral
  23.Srinivas NR, Shyu WC, Weiner RS, Tay LK, Greene DS, Barbhaiya RH. Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice. J Pharm Sci. 1995;84(12):1488–9.CrossRef PubMed
  24.Wang L, Zheng J, Maehara A, Yang C, Billiar KL, Wu Z, et al. Morphological and stress vulnerability indices for human coronary plaques and their correlations with cap thickness and lipid percent: an IVUS-based fluid–structure interaction multi-patient study. PLoS Comput Biol. 2015;11(12), e1004652. doi:10.​1371/​journal.​pcbi.​1004652 .CrossRef PubMed PubMedCentral
  25.Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204–12. doi:10.​1038/​ni.​2001 .CrossRef PubMed
  26.Thorp E, Subramanian M, Tabas I. The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur J Immunol. 2011;41(9):2515–8. doi:10.​1002/​eji.​201141719 .CrossRef PubMed PubMedCentral
  27.Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341–55. doi:10.​1016/​j.​cell.​2011.​04.​005 .CrossRef PubMed PubMedCentral
  28.Vanhove C, Bankstahl JP, Krämer SD, Visser E, Belcari N, Vandenberghe S. Accurate molecular imaging of small animals taking into account animal models, handling, anaesthesia, quality control and imaging system performance. EJNMMI Phys. 2015;2(1):31. doi:10.​1186/​s40658-015-0135-y .CrossRef PubMed PubMedCentral
  29.Shen J, Townsend R, You X, Shen Y, Zhan P, Zhou Z, et al. Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. Clin Drug Investig. 2014;34(2):117–26. doi:10.​1007/​s40261-013-0153-2 .CrossRef PubMed PubMedCentral
  
• 作者单位：Romana Meletta (1)
  Adrienne Müller Herde (1)
  Patrick Dennler (2)
  Eliane Fischer (2)
  Roger Schibli (1) (2)
  Stefanie D. Krämer (1)
  
  1. Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 3/4, CH-8093, Zurich, Switzerland
  2. Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, OIPA10A, 5232, Villigen-PSI, Switzerland
  
• 刊物主题：Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology;
• 出版者：Springer Berlin Heidelberg
• ISSN：2191-219X

文摘

Background The inflammatory nature of atherosclerosis provides a broad range of potential molecular targets for atherosclerosis imaging. Growing interest is focused on targets related to plaque vulnerability such as the co-stimulatory molecules CD80 and CD86. We investigated in this preclinical proof-of-concept study the applicability of the CD80/CD86-binding fusion protein belatacept as a probe for atherosclerosis imaging.